US WorldMeds Acquires Orbus Therapeutics, Expanding Commitment to Rare Diseases and Advancing Eflornithine in Adult Malignant Glioma
Acquisition builds on Phase 3 STELLAR study results showing clinically meaningful improvements in overall and progression-free survival in the subgroup of patients with recurrent IDH-mutant Grade 3 astrocytoma LOUISVILLE, Ky. and MENLO PARK, Calif., Oct. 27, 2026 /PRNewswire/ -- US...
Covered in this story
Call it yourself
No calls on $PARK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Park Dental Partners →Dalsna Finance is currently tracking 5 stories mentioning Park Dental Partners, the earliest published 27 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.